Introduction {#s01}
============

Several human syndromes present with atopy and connective tissue abnormalities providing genetic links between allergic findings---such as atopic dermatitis, elevated serum IgE, and eosinophilic esophagitis---and joint hypermobility, retained primary dentition, or vascular malformation ([@bib14]; [@bib26]; [@bib1]; [@bib12]; [@bib7]; [@bib20]). Enhanced cell-intrinsic TGF-β activity has been described in several connective tissue, hypermobility, and vascular phenotypes ([@bib6]; [@bib18]; [@bib27]), whereas dominant-negative *STAT3* mutations have been shown to predispose individuals to similar joint and vascular abnormalities as part of the autosomal dominant hyper-IgE syndrome ([@bib11]). However, whether these disorders are mechanistically linked and how altered STAT3 or TGF-β signaling may promote atopy remain unclear.

In vitro knockdown of STAT3 has been shown to potentiate TGF-β--mediated SMAD2/3 activation in human cancer lines ([@bib19]). Conversely, overexpression of the constitutively active STAT3 construct (STAT3C) was shown to have a negative effect on TGF-β signaling via SMAD3--STAT3 complex formation in HeCaT cells in vitro ([@bib39]). This negative effect appeared to be dependent on the DNA-binding domain of STAT3, without which SMAD3 and STAT3 were unable to complex. Overexpression of this same construct in HeLa cells was also associated with up-regulation of ERBB2-interacting protein (ERBIN; [@bib15]), a SMAD anchor for receptor activation (SARA) and SMAD-binding protein that negatively regulates TGF-β signaling through cytoplasmic sequestration of SMAD2/3 ([@bib33]).

Results {#s02}
=======

Using an established SMAD-reporter cell line ([@bib30]), we found that STAT3 activating cytokines IL-6 and IL-11 significantly suppressed TGF-β--mediated reporter activity in short-term cultures ([Fig. 1 A](#fig1){ref-type="fig"}). Suppression required IL-6 or IL-11 pretreatment, with a maximal effect occurring at 72 h suggesting a transcriptional effect, and correlated proportionally with induction of ERBIN protein expression induced by IL-6 ([Fig. 1 B](#fig1){ref-type="fig"}). ERBIN protein expression proved essential for IL-6--mediated pathway suppression, as the suppressive effects observed after pretreatment were completely abolished by ERBIN silencing ([Fig. 1 C](#fig1){ref-type="fig"}). ERBIN is known to form protein scaffolds and can complex with SMAD2/3, sequestering it in the cytoplasm, thus preventing transcriptional activity in a manner similar to that seen with STAT3C overexpression in vitro ([@bib33]; [@bib39]). Using gel filtration chromatography, we identified a large molecular weight fraction containing SMAD2/3, STAT3, and ERBIN and that contained pSMAD2/3 after STAT3 activation by IL-6 (Fig. S1 A). By immunoprecipitation, we confirmed that, after STAT3 activation and associated induction of ERBIN, a complex containing SMAD2/3 and STAT3 can form and that ERBIN was required, as knockdown prevented this complex from forming ([Fig. 1 D](#fig1){ref-type="fig"}). Furthermore, we found that this complex containing STAT3 was necessary for the suppressive effects of ERBIN, as STAT3 knockdown abolished the reduction in TGF-β pathway activation seen after ERBIN overexpression ([Fig. 1 E](#fig1){ref-type="fig"}).

![**STAT3 negatively regulates TGF-β pathway activation via ERBIN.** (A) TGF-β--induced SMAD pathway activation in 293T SMAD-reporter line after short-term culture in the presence of STAT3-activating cytokine IL-6 or IL-11. (B) TGF-β--mediated pathway activation after stimulation in a SMAD-reporter cell line treated with IL-6 (top) and corresponding immunoblot of ERBIN expression from each culture (bottom). (C) TGF-β--induced SMAD-reporter activity after ERBIN knockdown (*siERBB2IP*) or transfection with scrambled siRNA (*siControl*) after 3-d culture in the presence or absence of IL-6. (D) Representative immunoblot of ERBIN, STAT3, and/or SMAD2/3 after immunoprecipitation (IP) of STAT3 or SMAD2/3 as indicated in 293T cells after siRNA-mediated knockdown of ERBIN in the presence or absence of STAT3 activation induced by treatment with IL-6. (E) TGF-β--induced SMAD-reporter activity after either STAT3 knockdown (*siSTAT3*) or scrambled siRNA transfection and cotransfection with either wild-type ERBIN (*ERBB2IP^WT^*) or empty vector (EV). (F) TGF-β--induced activation in SMAD-reporter line after transfection with empty vector, wild-type *STAT3* (*STAT3^WT^*), or dominant-negative *STAT3*-mutant (*STAT3^mut^*) constructs. (G) TGF-β--induced SMAD-reporter activity after siRNA-mediated STAT3 silencing relative to activity after scrambled siRNA transfection. (H) *ERBB2IP* mRNA expression in purified control pan-T cells after treatment with 50 ng/ml IL-6. (I) Representative immunoblot of GFP after MYC immunoprecipitation in 293T cells in which MYC-tagged wild-type *STAT3* (MYC-*STAT3^WT^*) or dominant-negative *STAT3* (MYC-*STAT3^mut^*) constructs and GFP-tagged ERBIN wild-type (GFP-*ERBB2IP^WT^*) constructs were overexpressed in the presence or absence of STAT3 activation by IL-6. Data are representative or combined from at least three independent experiments and shown as the mean ± SEM. Unpaired two-tailed Student's *t* tests and Wilcoxon matched pairs were used where appropriate. \*, P \< 0.05; \*\*, P \< 0.005; \*\*\*, P \< 0.001. AU, arbitrary units.](JEM_20161435_Fig1){#fig1}

To determine what effect dominant-negative *STAT3* mutations found in humans might have on TGF-β signaling, we first overexpressed STAT3-mutant (*STAT3^mut^*) constructs in the SMAD-reporter cell line and found significant enhancement of responses to TGF-β ([Fig. 1 F](#fig1){ref-type="fig"}); similar deregulation of SMAD-reporter activity was seen after STAT3 knockdown ([Fig. 1 G](#fig1){ref-type="fig"}). Because mutant STAT3 protein is expressed in these *STAT3^mut^* individuals, we next sought to determine whether increased TGF-β activity in vitro resulted from impaired complex formation or reduced ERBIN expression. We confirmed that STAT3 activation by IL-6 was capable of inducing *ERBB2IP* expression in primary human T cells ([Fig. 1 H](#fig1){ref-type="fig"}; [@bib15]). However, overexpression of mutant *STAT3* (MYC-*STAT3^mut^*) with wild-type ERBIN (GFP-*ERBB2IP^WT^*) showed no impairment in complex formation relative to wild-type *STAT3* (MYC-*STAT3^WT^*; [Fig. 1 I](#fig1){ref-type="fig"}), indicating that the increased TGF-β activity associated with *STAT3^mut^* transfection was not caused by altered complex formation. We confirmed significantly reduced ERBIN protein expression in primary dermal fibroblasts (from both SH2 and DNA-binding mutant individuals) as well as in CD4 cells from *STAT3^mut^* patients ([Fig. 2, A and B](#fig2){ref-type="fig"}).

![**ERBIN expression is reduced in *STAT3^mut^* patient cells and in newly identified individuals with an *ERBB2IP* mutation.** (A, top) Representative immunoblot showing ERBIN expression in primary dermal fibroblasts from control, *STAT3^mut^*, and *ERBB2IP^mut^* patients. Lines indicate rearranged segments of one blot. (Bottom) Integrated densitometry of combined data comparing control (*n* = 4) with *STAT3^mut^* (SH2 mutants, *n* = 2; DNA-binding mutants, *n* = 2) or *ERBB2IP^mut^* (*n* = 2) individuals. (B) ERBIN expression in naive (CD45RO^−^) or memory (CD45RO^+^) CD4 T cells from control (*n* = 15), *STAT3^mut^* (*n* = 17), and *ERBB2IP^mut^* (*n* = 3) patients. (C) Pedigree, chromatogram, and schematic of mutation (c.1588G\>T p.\[D530Y\]) in *ERBB2IP* identified in a family with a dominant congenital allergic disorder with connective tissue features. LRR, leucine rich repeat domain; PDZ, PSD95-Dlg1-zo-1--like domain; SSID, SMAD--SARA interacting domain. (D) Representative immunoblot of GFP after MYC immunoprecipitation (IP) in 293T cells in which MYC-tagged wild-type *STAT3* (MYC-*STAT3^WT^*) and GFP-tagged ERBIN-mutant (GFP-*ERBB2IP^mut^*) or wild-type (GFP-*ERBB2IP^WT^*) constructs were overexpressed in the presence or absence of STAT3 activation by IL-6. (E) Effect of wild-type ERBIN (*ERBB2IP^WT^*) or mutant ERBIN (*ERBB2IP^mut^*) on TGF-β--induced SMAD-reporter activity. AU, arbitrary units. Data are representative or combined from at least three independent experiments and represented as the mean ± SEM. Paired and unpaired two-tailed Student's *t* tests and Mann-Whitney tests were used where appropriate. \*, P \< 0.05; \*\*, P \< 0.005; \*\*\*, P \< 0.001.](JEM_20161435_Fig2){#fig2}

Subsequently, we identified a family with a dominantly inherited symptom complex that shared both allergic and nonimmunological connective tissue features with *STAT3^mut^* patients, including elevated IgE, eosinophilic esophagitis, joint hypermobility, and vascular abnormalities ([Table 1](#tbl1){ref-type="table"} and [Fig. 2 C](#fig2){ref-type="fig"}; for phenotypic comparisons, see Table S1). Neither novel nor disease-causing variants were identified at *STAT3*, *TNXB*, *COL3A1*, *TGFBR1*, *TGFBR2*, *SMAD3*, *TGFB2*, or *TGFB3*. Exome sequencing did identify a rare disease-segregating variant (c.1588G\>T p.\[D530Y\]) in *ERBB2IP* (allelic frequency 0.000076 in the Exome Aggregation Consortium database; not present in 1000 Genomes database), the gene encoding ERBIN ([Fig. 2 C](#fig2){ref-type="fig"}). This variant was predicted to be pathogenic and was associated with significantly reduced ERBIN protein expression in primary dermal fibroblasts and CD4 cells (*ERBB2IP^mut^*; [Fig. 2, A and B](#fig2){ref-type="fig"}). The index patient's father had succumbed to an acute cardiac event related to hypertrophic cardiomyopathy at age 28 yr, a phenotype seen in *ERBB2IP* knockout mice ([@bib32]). In addition to reduced ERBIN protein expression, the variant also impaired ERBIN--STAT3 complex formation, as the mutant construct (GFP-*ERBB2IP^mut^*) failed to coimmunoprecipitate with *STAT3^WT^* after overexpression ([Fig. 2 D](#fig2){ref-type="fig"}). Although the mutant failed to suppress TGF-β signaling in the SMAD-reporter line, a dominant-negative effect on endogenous ERBIN was not observed, as no enhancement in SMAD-reporter activity was seen after *ERBB2IP^mut^* overexpression ([Fig. 2 E](#fig2){ref-type="fig"}).

###### Immunological findings among *ERBB2IP^mut^* individuals

           Cell counts                                                         Serum Ig         Antibody titers              Lymphocyte subsets   Serum tryptase                                                                                                             
  -------- --------------------------------------------------- --------------- ------------- -- ----------------- ---------- -------------------- ---------------- -- --------- --------------- -- ------------- -------- -- ------------ ------- -- ------------ ---------- ---------
           *cells/µL*                                          *cells/µL*      *cells/µL*       *mg/dL*           *mg/dL*    *mg/dL*              *IU/ml*             *IU/ml*   *\>1.3 µg/ml*      *cells/µl*    *%*         *cells/µl*   *%*        *cells/µl*   *%*        *ng/ml*
  Ref.     1,320-- 3,570                                       1,780-- 5,380   40--540          700-- 1,600       91--499    34--342              0--90               \>0.15    16/23              359-- 1,565   13--50      178--853     3--16      59--329      0.8--3.6   \<11.4
  14-y M   3,290-- 4,550[^c^](#ttbl1n4){ref-type="table-fn"}   1,430-- 2,410   520-- 2,880      368-- 898         16--51     45--115              333--898            2.21      21/23              1,670         7.2         952          2          438          1.5        5.3
  11-y F   4,450-- 7,720[^c^](#ttbl1n4){ref-type="table-fn"}   1,410-- 1,860   90--680          693--737          68--89     90--102              10--98              0.35      20/23              2,506         9           1,501        5.1        794          3.4        4.2
  43-y M   2,060--3,010                                        1,810--4,290    80--310          946--1,290        137--194   55--82               20--200             1.62      13/23              1,457         20          461          5.5        381          1.7        5.2

Abbreviations used: AEC, absolute eosinophil count; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; F, female; M, male; Ref., reference range; y, year old.

T cell memory was defined as CD45RO^+^.

B cell memory was defined as CD27^+^.

Increased total lymphocyte counts and reduced memory populations relative to adult reference values are a result of the young age of these individuals and do not represent defective memory formation or other pathology.

Reduced ERBIN expression in both *STAT3^mut^* and *ERBB2IP^mut^* patient cells and impaired STAT3--ERBIN complex formation in *ERBB2IP^mut^* patient cells did not affect total cellular pSMAD2/3 levels in response to TGF-β ([Fig. 3 A](#fig3){ref-type="fig"}) but was associated with increased nuclear SMAD2/3 levels in primary T cells ([Fig. 3 B](#fig3){ref-type="fig"}) and increased nuclear pSMAD2/3 in lymphocytes ([Fig. 3, C and D](#fig3){ref-type="fig"}), consistent with the role of ERBIN in sequestering cytoplasmic SMAD2/3. The same effect could be observed after overexpression of *STAT3^mut^* in 293T cells, which resulted in enhanced nuclear pSMAD2/3 that could be partially normalized by cotransfection with *ERBB2IP^WT^* ([Fig. 3 E](#fig3){ref-type="fig"}).

![**TGF-β--induced nuclear SMAD2/3 is increased in *STAT3^mut^* and *ERBB2IP^mut^* lymphocytes.** (A) Total pSMAD2/3 MFI shown as mean ± SEM in control (*n* = 4), *STAT3^mut^* (*n* = 2), or *ERBB2IP^mut^* (*n* = 2) CD4 lymphocytes after 2-h stimulation with TGF-β. (B) Representative immunoblot of nuclear (Nuc; bottom) and cytoplasmic (Cyto; top) SMAD2/3 in *ERBB2IP^mut^* and *STAT3^mut^* patient PBMCs compared with controls after TGF-β stimulation. Integrated densitometry normalized to lamin A or HSP90 is provided above each condition. (C and D) Representative quantification (C) and images (D) from Amnis ImageStream analysis (\>1200 cells per condition) of nuclear pSMAD2/3 with and without TGF-β stimulation in control, *STAT3^mut^*, and *ERBB2IP^mut^* patient lymphocytes using a DAPI nuclear mask, shown as geometric mean ± 95% confidence interval. BF, brightfield; Unstim, unstimulated. Bar, 40 µm. (E) Representative immunoblot of nuclear (bottom) and cytoplasmic (top) pSMAD2/3 after cotransfection with a dominant-negative *STAT3* (*STAT3^mut^*) construct and empty vector (EV), wild-type ERBIN (*ERBB2IP^WT^*), or with only the two corresponding empty vectors (EV\[2\]). Integrated densitometry normalized to lamin A or β-actin is provided above each condition. Data are representative or combined from at least two independent experiments. Unpaired two-tailed Student's *t* tests and Mann-Whitney tests were used where appropriate. \*\*, P \< 0.005.](JEM_20161435_Fig3){#fig3}

TGF-β is critical for FOXP3 expression after CD4 cell activation and is likely essential for regulatory T cell (T reg cell) ontogeny ([@bib36]; [@bib31]). To determine the potential in vivo consequences of reduced ERBIN expression and associated TGF-β pathway deregulation in *STAT3^mut^* and *ERBB2IP^mut^* patients, we began by examining these outcomes in primary cells. 4-h T cell stimulation ex vivo resulted in significantly higher FOXP3 expression among *STAT3^mut^* and *ERBB2IP^mut^* patient total CD4 lymphocytes compared with controls ([Fig. 4 A](#fig4){ref-type="fig"}, left). This agreed with increased T reg cells ex vivo (defined as CD4^+^FOXP3^+^CD25^bright^CD127^low^) among *STAT3^mut^* and *ERBB2IP^mut^* patient CD4 memory (CD45RO^+^) cells compared with controls ([Fig. 4 A](#fig4){ref-type="fig"}, right). In addition, to increased circulating T reg cells, naive CD4 T cells from *STAT3^mut^* and *ERBB2IP^mut^* patients more readily differentiated into inducible T reg cells (iT reg cells) in vitro ([Fig. 4 B](#fig4){ref-type="fig"}, bottom), an effect that was found to be dose dependent on TGF-β in control naive CD4 cells ([Fig. 4 B](#fig4){ref-type="fig"}, top) but independent of IL-2 concentration in our system, in controls as well as *STAT3^mut^* and *ERBB2IP^mut^* cells (Fig. S2, A and B). Furthermore, no difference in IL-2--induced STAT5 phosphorylation within *STAT3^mut^* patient T cells (Fig. S2 C) or in IL-6--mediated STAT3 phosphorylation within *ERBB2IP^mut^* patient T cells (Fig. S2 D) was found when compared with controls.

![**Increased TGF-β sensitivity in *STAT3^mut^* and *ERBB2IP^mut^* CD4 lymphocytes is associated with increased T reg cells and induced GATA3 expression in vitro.** (A, left) FOXP3 induction in total CD4^+^ T cells after short-term stimulation of control (*n* = 20), dominant-negative *STAT3*-mutant (*STAT3^mut^*; *n* = 13), and ERBIN-mutant (*ERBB2IP^mut^*; *n* = 3) individual cells. (Right) Prevalence of regulatory T cells (T reg) among memory (CD45RO^+^) cells from control (*n* = 20), *STAT3^mut^* (*n* = 12), and *ERBB2IP^mut^* (*n* = 3) patients. (B, top) Dose response of inducible regulatory T cells (iT reg) to TGF-β concentration in control naive CD4 lymphocytes in vitro. (Bottom) Percent iT reg cells obtained in cultures of control, *STAT3^mut^*, and *ERBB2IP^mut^* patient lymphocytes at the indicated concentrations of TGF-β. (C, top) Contour plot of FOXP3 and CD25 expression showing the spontaneous iT reg cell (FOXP3^+^CD25^bright^) population obtained after culture of naive CD4 lymphocytes with weak (0.5 µg/ml αCD3) TCR stimulation under nonskewing conditions, in the presence of IL-2. (Right) Combined data. (Bottom) Representative histograms of GATA3 expression among FOXP3^−^CD25^+^ cells from these same cultures (left) and combined data (right). (D) Relative quantitation of *IL4*, *IL4R*, and *GATA3* genes in Jurkat T cells after knockdown of STAT3 (*siSTAT3*), GATA3 (*siGATA3*), or scrambled control (*siControl*) under standard culture conditions (10% FCS, determined to contain 10% of maximal TGF-β activity \[media\]) or in the presence of exogenous TGF-β (media + 5 ng/ml). Data are representative or combined from at least three independent experiments and are represented as the mean ± SEM. Unpaired two-tailed Student's *t* tests and Mann-Whitney tests were used where appropriate. \*, P \< 0.05; \*\*, P \< 0.005; \*\*\*, P \< 0.001.](JEM_20161435_Fig4){#fig4}

The STAT3 DNA-binding domain was previously reported as necessary for STAT3--SMAD3 complex formation and negative regulation of TGF-β activation ([@bib19]). However, neither the observed increase in FOXP3 expression nor the increase in T reg cell number was dependent on the location of dominant-negative *STAT3* mutations (SH2 or DNA-binding domains; Fig. S2 E). Therefore, deleting the DNA-binding domain of STAT3C may have prevented ERBIN transcription and secondarily reduced complex formation rather than eliminating the requirement of that domain for ERBIN interaction.

During T cell activation, weak TCR signaling has been associated with development of both T helper type 2 cells (Th2 cells) and iT reg cells ([@bib37]; [@bib23]; [@bib38]). Although several mechanisms have been shown to contribute to Th2 cell skewing in this context, TGF-β pathway activation might directly contribute to both. In addition to promoting FOXP3 expression, TGF-β--dependent SMAD3 activation has been shown to potentiate the transcriptional activity of GATA3, the canonical Th2 transcription factor, through direct complex formation ([@bib4]). TGF-β has also been shown to induce IL-4Rα in a SMAD3-dependent manner in a mouse model ([@bib5]). Furthermore, dysregulated expression of GATA3 and GATA3 targets has been reported in syndromic and nonsyndromic allergy ([@bib12]; [@bib28]). To determine whether deregulated TGF-β signaling might contribute to either fate, naive CD4^+^ T cells were subjected to weak TCR-mediated activation with low-dose anti-CD3, co-stimulated with anti-CD28, and cultured under nonskewing conditions in the presence of IL-2 without exogenous TGF-β. Increased spontaneous iT reg cells were observed in both *STAT3^mut^* and *ERBB2IP^mut^* patient cultures compared with controls ([Fig. 4 C](#fig4){ref-type="fig"}, top), which could be recapitulated in control naive CD4 cells after siRNA-mediated knockdown of *STAT3* or *ERBB2IP* (Fig. S2 E), and were associated with a significant increase in GATA3 expression from activated (CD25^+^) FOXP3^−^ cells in these same cultures ([Fig. 4 C](#fig4){ref-type="fig"}, bottom). Ex vivo, corresponding increases in T reg cells and total FOXP3 expression ([Fig. 3 A](#fig3){ref-type="fig"}) also did not appear dependent on the location of *STAT3* mutations (Fig. S2 F).

Expression of both GATA3 and IL-4 is canonically associated with lineage-committed effector Th2 cell populations. However, GATA3 can drive a multitude of functions beyond CD4 effector function, including but not limited to tissue ILC2s, which could further mucosal allergic responses ([@bib35]). In T reg cells, GATA3 expression appears to both limit FOXP3 and promote tolerance at some stages of expression in mice ([@bib40]; [@bib42]; [@bib44]), whereas in humans, coexpression may be pathogenic and has been associated with allergic disease ([@bib12]; [@bib28]; [@bib16]). Because manipulation of primary cells and expression of these targets may be subject to disease state (e.g., atopic dermatitis flare), we began by examining the effects of TGF-β on the IL-4/IL-4Rα/GATA3 axis in Jurkat T cells. Both exogenous TGF-β treatment and STAT3 knockdown significantly induced *IL4*, *IL4R*, and *GATA3* transcript levels ([Fig. 4 D](#fig4){ref-type="fig"} and Fig. S3 A), whereas *TBX21* (encoding T-BET, the canonical Th1 transcription factor) levels were unaffected by TGF-β treatment (Fig. S3 B). Transcription of IL-4 appeared to be co-dependent on GATA3, as GATA3 knockdown significantly reduced responsiveness to TGF-β ([Fig. 4 D](#fig4){ref-type="fig"}); however, consistent with the previous study in mice, *IL4R* induction by TGF-β appeared to have no such dependence on GATA3 coexpression ([@bib5]).

To investigate whether an atopic predisposition may exist in vivo, we focused our efforts on IL-4Rα expression. In mice, IL-4Rα expression on naive CD4 cells has been shown to directly and positively correlate with the number of Th2 effectors that are ultimately formed ([@bib22]). IL-4Rα--mediated STAT6 activation is also critical for class switch recombination to IgE ([@bib13]). First, we determined that IL-4Rα surface expression in Jurkat T cells was responsive to TGF-β treatment and that this effect could be partially attenuated by pretreatment with IL-6 (Fig. S3 C). Examining naive lymphocytes ex vivo, we subsequently found that *STAT3^mut^* and *ERBB2IP^mut^* patients had significantly greater IL-4Rα expression compared with controls ([Fig. 5, A and B](#fig5){ref-type="fig"}), and brightly IL-4Rα--positive (IL-4R^hi^) cells had greater STAT6 phosphorylation in response to IL-4 (Fig. S3 D). We further found that the STAT6 B cell target CD23 was expressed at higher levels in CD19^+^ lymphocytes from *STAT3^mut^* and *ERBB2IP^mut^* patients basally, as others have reported in *STAT3^mut^* patients ([@bib8]). After IL-4 stimulation, a significantly greater induction of CD23 in *STAT3^mut^* naive B cells and both *STAT3^mut^* and *ERBB2IP^mut^* memory B cells was also seen compared with controls ([Fig. 5 C](#fig5){ref-type="fig"} and Fig. S3 E).

![**Increased functional IL-4Rα expression in *STAT3^mut^* and *ERBB2IP^mut^* naive lymphocytes promotes TGF-β--dependent GATA3 expression in CD4 T cells.** (A) Contour plots demonstrating expression of IL-4Rα ex vivo on naive (CD27^−^) B cells (top) and contour plots showing CD27 and IL-4Rα coexpression and gating strategy of naive (CD45RO^−^) T cells (bottom) from control, *STAT3^mut^*, and *ERBB2IP^mut^* patients. (B) Combined ex vivo IL-4Rα expression on naive lymphocytes from control (*n* = 19), *STAT3^mut^* (*n* = 17), and *ERBB2IP^mut^* (*n* = 3) individuals. MFI on naive (CD27^−^) B cells (left) and percentage of naive (CD27^−^) B cells (middle) and of CD27^+^ naive (CD45RO^−^) CD4 cells (right) expressing IL-4Rα are shown. (C) Percentage of naive (CD27^−^) B cells from controls (*n* = 8), *STAT3^mut^* (*n* = 8), and *ERBB2IP^mut^* (*n* = 3) individuals expressing the STAT6-target CD23 ex vivo or after short-term stimulation with IL-4 as indicated. (D) IL-4Rα and resulting GATA3 expression in control, *STAT3^mut^*, and *ERBB2IP^mut^* naive CD4 T cells after activation (CD69^+^) with weak TCR stimulation under nonskewing conditions in the presence or absence of a TGF-β1--neutralizing antibody (αTGFβ1), a TGFβR1 inhibitor (TGFβR1i), or a selective SMAD3 inhibitor (SMAD3i). Contour plots (left) and combined GATA3 MFI (right) are shown. (E) Comparison of GATA3 expression in activated (CD69^+^) control naive CD4 cells, as normalized MFI, cultured with 10 µg/ml neutralizing IL-4 antibody (αIL-4) or SMAD3i under the same conditions as in D. Data are representative or combined from at least three independent experiments and are represented as the mean ± SEM. Unpaired two-tailed Student's *t* tests and Mann-Whitney tests were used where appropriate. \*, P \< 0.05; \*\*, P \< 0.005; \*\*\*, P \< 0.001.](JEM_20161435_Fig5){#fig5}

TCR-mediated activation of CD4 lymphocytes has been shown to enhance IL-4Rα expression independently of IL-4 expression ([@bib17]); however, exogenous TGF-β alters naive CD4 proliferation and homeostasis ([@bib21]). Many compensatory mechanisms exist to tightly regulate and limit the immunological effects of exogenous TGF-β pathway activation ([@bib10]; [@bib25]; [@bib43]), and the absence of reported allergic phenotypes among Marfan syndrome patients (caused by *FBN1* mutations) and arterial tortuosity syndrome patients (caused by *SLC2A10* mutations) provides clinical evidence to suggest that cell-intrinsic defects in TGF-β pathway activation are critical to atopic predisposition in this context ([@bib9]; [@bib6]). To circumvent this problem and determine the effect that intrinsic deregulation of TGF-β pathway signaling may have on IL-4Rα expression, we again cultured naive CD4 lymphocytes with weak TCR stimulation, but, this time, in the presence or absence of selective TGF-β pathway inhibition or a neutralizing TGF-β antibody (αTGFβ1), and looked for an effect on IL-4Rα expression and associated GATA3 induction. After short-term culture of naive CD4 cells under nonskewing conditions, elevated IL-4Rα expression and, more importantly, GATA3 induction in CD69^+^ activated cells were greater in *STAT3^mut^* and *ERBB2IP^mut^* patients compared with controls ([Fig. 5 D](#fig5){ref-type="fig"}, and Fig. S4, A and B). Selective SMAD3 inhibition (SMAD3i) had the greatest effect on normalizing GATA3 expression in *STAT3^mut^* and *ERBB2IP^mut^* patient lymphocytes, an effect comparable with IL-4 neutralization ([Fig. 5 E](#fig5){ref-type="fig"}), rendering levels below that of untreated controls, whereas the TGFβR1 inhibitor (TGFβR1i) had a modest effect, and αTGFβ1 resulted in only a nonsignificant reduction. Control naive CD4 cells also showed significant reductions in IL-4Rα and associated GATA3 expression after SMAD3i and TGFβR1i treatment ([Fig. 5 D](#fig5){ref-type="fig"} and Fig. S4 B).

These findings were associated with increased ex vivo expression of the GATA3-dependent Th2 cytokines, IL-4, IL-5, and IL-13 among *STAT3^mut^* and *ERBB2IP^mut^* patients ([Fig. 6 A](#fig6){ref-type="fig"}). Again, this appeared to be independent of the mutated *STAT3* domain and, importantly, occurred in isolation from any disruption in Th1 cytokine production ([Fig. 6 B](#fig6){ref-type="fig"}) and in *ERBB2IP^mut^* patients was not accompanied by other CD4 defects known to occur in *STAT3^mut^* patients within Th17 and T follicular helper cell compartments caused by defective STAT3 signaling ([Fig. 6 C](#fig6){ref-type="fig"}). Clinically, these findings manifest as shared allergic and connective tissue phenotypes. However, mucosal susceptibility to candida, impairment in T cell and B cell memory, and class switching appear unique to *STAT3^mut^* individuals. One *ERBB2IP^mut^* individual has recently developed clinically asymptomatic hypogammaglobulinemia but has protective antibody responses ([Table 1](#tbl1){ref-type="table"} and Table S1).

![**Increased Th2 cytokine production in *STAT3^mut^* and *ERBB2IP^mut^* individual CD4 lymphocytes ex vivo.** (A) Ex vivo cytokine expression in control (*n* = 10), *ERBB2IP^mut^* (*n* = 3), and *STAT3^mut^* memory (*n* = 9; CD45RO^+^) CD4 T cells. (B) Th2 cytokine expression of *STAT3*-mutant patients (*STAT3^mut^*) with SH2-domain mutations (*n* = 3) or DNA-binding--domain mutations (*n* = 4). (C) Ex vivo IL-17 expression in control (*n* = 6) and *ERBB2IP^mut^* (*n* = 3) and IL-21 expression in control (*n* = 4), *ERBB2IP^mut^* (*n* = 2), and *STAT3^mut^* memory (*n* = 2; CD45RO^+^) CD4 T cells. Data are combined from at least two independent experiments and are represented as the mean ± SEM. Mann-Whitney tests were used. \*, P \< 0.05; \*\*, P \< 0.005.](JEM_20161435_Fig6){#fig6}

Discussion {#s03}
==========

These results suggest that STAT3 activation promotes ERBIN expression and negatively regulates TGF-β activity by the formation of a STAT3--ERBIN--SMAD2/3 complex, thereby sequestering SMAD2/3 in the cytoplasm. Impaired basal STAT3 signaling reduces ERBIN expression and deregulates TGF-β pathway activation, leading to increased circulating T reg cells and functional IL-4Rα expression on naive lymphocytes in humans. TGF-β can drive IL-4/IL-4R/GATA3 expression in vitro, and enhanced TGF-β--induced SMAD2/3 activity correlates with increased Th2 cytokine--expressing memory cells and elevated serum IgE in *STAT3^mut^* and *ERBB2IP^mut^* patients. These findings may help explain why these syndromes share allergic and nonimmunological phenotypes. Moreover, the IL-4Rα/GATA3 axis can be restrained in vitro with SMAD3 inhibition in this context, suggesting a novel pathway for treatment of these disorders and potentially for atopic diatheses associated with STAT3 or TGF-β pathway disruptions more generally. Furthermore, IL-4Rα blockade, used successfully in a variety of atopic disorders ([@bib41]; [@bib3]; [@bib2]; [@bib34]), may be more effective in patients with evidence of disrupted STAT3 or enhanced TGF-β signaling.

Materials and methods {#s04}
=====================

Human subjects {#s05}
--------------

All *ERBB2IP^mut^* patients and family members provided informed consent on National Institutes of Health (NIH) institutional review board--approved research protocols designed to study atopy (NCT01164241) and hyper-IgE syndromes (NCT00006150). Comprehensive histories, review of all available outside records, serial clinical evaluations, and therapeutic interventions were all performed at the Clinical Center of NIH. All clinical immunological laboratory tests were performed by the Department of Laboratory Medicine at NIH. *STAT3^mut^* patients were actively enrolled on a natural history protocol and followed at NIH having provided informed consent for the study (NCT00006150).

Genetic sequencing {#s06}
------------------

Exome sequencing and data analysis were performed as previously described to identify *ERBB2IP^mut^* patients ([@bib45]). Novel candidate variants were filtered by 1000 Genomes, dbSNP, and Exome Aggregation Consortium databases, as well as by an in-house database with over 500 exomes. Candidate variants were identified based on an autosomal-dominant pattern of inheritance. Segregating mutations identified by whole-exome sequencing were verified by Sanger sequencing of the candidate gene as previously described ([@bib45]). Before study initiation, *STAT3^mut^* patients had been identified clinically and confirmed genetically by Sanger sequencing to have dominant-negative *STAT3* mutations as previously described ([@bib14]).

Antibodies, siRNAs, and expression plasmids {#s07}
-------------------------------------------

For flow cytometric analyses, the following antibodies were used: anti-CD3 AF700/APC, anti-CD4 BUV395/FITC/APC-H7, anti-CD19 APC/BV605, anti-CD25 PE-Cy7/APC-H7, anti-CD27 v450, anti-CD69 FITC, anti-CD127 AF647, anti-GATA3 AF488/AF647, anti--IFN-γ v450, anti--IL-2 FITC, anti--IL-4 PE-Cy7, anti--IL-5 PE, anti--IL-13 BV711, anti-pSMAD2/3 PE/AF647, anti-pSTAT3 (Y705) AF647, anti-pSTAT5 (Y694) Pacific blue, and anti-pSTAT6 (Y641) APC (BD); anti-FOXP3 efluor450, anti--IL-17A APC, anti--IL-21 efluor660, and anti-CD23 PE-Cy7/FITC (eBioscience); anti-CD45RO Texas Red PE (Beckman Coulter); and anti-CD124 (IL-4Rα) PE (BioLegend). LIVE/DEAD Fixable blue and aqua stains (Thermo Fisher Scientific) were used for flow cytometry, and DAPI was used for Amnis ImageStream flow cytometry.

The following were used for immunoblotting: anti--β-actin, anti--β-tubulin, anti-HSP90, anti--IL-4Rα, anti--lamin A/C, anti-pSMAD2/3, anti-SMAD2/3, and anti-STAT3 (Cell Signaling Technology); anti-ERBB2IP (Santa Cruz Biotechnology, Inc.; Proteintech); and anti--turbo GFP (OriGene). Appropriate HRP-conjugated secondary antibodies were used for immunoblotting (Santa Cruz Biotechnology, Inc.). For immunoprecipitation, anti-STAT3, anti-SMAD2/3 monoclonal antibodies, or MYC sepharose and STAT3 sepharose (Cell Signaling Technology) were used.

Silencer select siRNAs directed against *ERBB2IP* and *STAT3* and control siRNAs (Thermo Fisher Scientific) were used for knockdown experiments. The wild-type ERBIN (*ERBB2IP^WT^*) plasmid was generated by cloning the cDNA open reading frame (NCBI RefSeq accession no. [NM_001253697](NM_001253697)[.1](.1)) into the pCMV6-AC-GFP vector (OriGene). The ERBIN-mutant clone (*ERBB2IP^mut^*) was generated using site-directed mutagenesis introducing c.1588G\>T p.(D530Y); both plasmids were confirmed by restriction digest on Southern blots and by Sanger sequencing (GenScript). Wild-type and dominant-negative *STAT3*-mutant (K658E and N647D; *STAT3^mut^*) and wild-type *STAT3* (*STAT3^WT^*) Myk-DDK--tagged plasmids were provided by S.M. Holland.

PBMC preparation and stimulation {#s08}
--------------------------------

PBMCs were separated by Ficoll (Ficoll-Paque PLUS; GE Healthcare) gradient centrifugation. Naive CD4 T cells and pan-T cells were isolated by negative selection using magnetic-activated cell-sorting purification (Miltenyi Biotec) and used for transfections or cultures as indicated. STAT3, STAT5, and STAT6 phosphorylation was detected after 25-min stimulation with 100 ng/ml IL-6, 40 U/ml IL-2 (PeproTech), or 50 ng/ml IL-4 (R&D Systems), respectively, as previously described ([@bib24]). CD23 induction was measured after 16-h stimulation with 50 ng/ml IL-4. SMAD2/3 phosphorylation was assessed after TGF-β1 (5 ng/ml; R&D Systems) stimulation at the concentrations indicated for 2 h (unless otherwise shown).

Cell cultures {#s09}
-------------

Primary dermal fibroblasts from *ERBB2IP^mut^*, *STAT3^mut^*, or healthy donors were grown in MEM supplemented with 20% fetal bovine serum and penicillin-streptomycin-glutamine (Thermo Fisher Scientific). 293T cells were cultured in IMDM with 10% FBS and penicillin-streptomycin-glutamine. Transfection of 293T cells with plasmids or siRNAs was accomplished with Nucleofector V (Lonza). Isolated naive primary CD4^+^ T cells were cultured in X-VIVO 15 media (Lonza). Plate-bound anti-CD3 (5 µg/ml unless otherwise indicated; eBioscience), soluble anti-CD28 (1 µg/ml; BD), and IL-2 (20 U/ml unless otherwise indicated; PeproTech) were used in nonskewing and iT reg cell conditions; TGF-β1 (R&D Systems) was used in iT reg cell cultures as indicated. When specified, a neutralizing anti-(α)TGFβ1 antibody (20 µg/ml; R&D Systems), a small molecule ALK5 inhibitor (TGFβR1i) GW788388, or a selective SMAD3 inhibitor (SMAD3i) SIS3 (Sigma-Aldrich) were added at 1 and 5 µM to nonskewing cultures of naive CD4 cells. To test specificity and inhibitory activity on TGF-β pathway activation, these inhibitors were added to the 293T SMAD-reporter line for 12 h before stimulation with TGF-β at the indicated concentrations.

Western blotting and immunoprecipitation {#s10}
----------------------------------------

A total of 50 µg of protein was isolated as previously described ([@bib29]), and nuclear and cytoplasmic fractions were obtained as indicated using an NE-PER kit (Thermo Fisher Scientific) following the manufacturer's protocol. For immunoprecipitation, after the indicated transfection and/or stimulation, 293T cells were lysed in immunoprecipitation lysis buffer (1× Mini protease inhibitor with EDTA \[Roche\], 20 mM Tris-HCl, pH 7.75, 140 mM NaCl, 1% Triton X-100, and 1 mM PMSF protease inhibitor cocktail \[Thermo Fisher Scientific\]), precleared, and immunoprecipitated using Protein A/G Plus agarose (Thermo Fisher Scientific) and monoclonal antibodies for SMAD2/3 or by using precoated sepharose beads for STAT3 and MYC (Cell Signaling Technology). Immunoblotting of whole cell lysates and immunoprecipitated proteins was performed using SDS-PAGE and transferred onto a polyvinylidene fluoride membrane as previously described ([@bib29]). ImageJ (National Institutes of Health) was used to quantify integrated density.

Gel filtration chromatography {#s11}
-----------------------------

Prepacked Superdex 200 10/30 GL columns (GE Healthcare) were used on an AKTA Chromatographic system (GE Healthcare). 293T cells cultured in the presence or absence of 50 ng/ml IL-6 (PeproTech) were mechanically lysed using detergent-free buffer (20 mM Tris-HCl, pH 7.5, 1 mM CaCl~2~, 1 mM MgCl~2~, and 1× protease inhibitors cocktail \[Roche\]). Samples were loaded onto the column (flow rate 0.5 ml/min; fraction 500 µl) and monitored by the eluent absorbance at 280 nm. High and medium molecular weight peaks (A1-15 and B15-14) were selected and subjected to Western blotting.

SMAD-reporter assay {#s12}
-------------------

293T cells stably expressing SMAD2/3 reporter construct (gift from A. Kitani, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) were stimulated with TGF-β1, and luciferase activity was measured as previously described ([@bib30]). In brief, the reporter line was pretreated with 50 ng/ml IL-6 or IL-11 (PeproTech) and/or transfected with constructs or siRNAs as indicated using Nucleofector kit V (Lonza), rested 12 h after transfection, and stimulated with 0.05--5 ng/ml TGF-β1 for 16 h. Cells were washed, and GFP fluorescence was measured. Next, cells were passively lysed, and luciferase activity was quantified using ONE-Glo reagent (Promega) and normalized to GFP fluorescent intensity.

Real-time PCR {#s13}
-------------

After treatment or transfection as indicated, mRNA was isolated from Jurkat T cells or from purified pan-T cells using the RNeasy kit (QIAGEN). Reverse transcription was performed using TaqMan reverse transcription reagents (Applied Biosystems; Thermo Fisher Scientific). Real-time PCR reactions were performed using TaqMan gene expression master mix (Applied Biosystems) and TaqMan gene expression assays probes for *IL4*, *IL4R*, *GATA3*, and *TBX21* (Thermo Fisher Scientific). *18S* RNA served as the control target. The reactions were run on a 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific), and mRNA copy number was calculated by relative quantitation.

Flow cytometry and Amnis ImageStream {#s14}
------------------------------------

Ex vivo intracellular cytokine staining for IL-2, IL-4, IL-5, IL-13, IL-17A, IL-21, and IFN-γ after PMA and ionomycin stimulation was performed as previously described ([@bib45]). Ex vivo T reg cell staining was performed using anti-CD3, CD4, CD25, CD45RO, CD127, and FOXP3 antibodies as previously described ([@bib24]). Induction of FOXP3 was assessed after PMA and ionomycin stimulation for 4 h. iT reg cell and nonskewing cultures were stained for CD4, CD25, FOXP3, and GATA3 or IL-4Rα where indicated. For iT reg cell and nonskewing cultures, a FOXP3/transcription factor--staining buffer set was used (eBioscience). Total pSMAD2/3 staining was performed using the FOXP3 buffer set according to the manufacturer's instructions. Phospho-STAT staining was performed as previously described (using IL-2, -4, and -6; [@bib24]). Ex vivo IL-4Rα expression and basal and IL-4--induced CD23 expression were obtained by staining live cells followed by fixation in 4% paraformaldehyde. IL-4Rα levels in cultured naive CD4^+^ T cells were accomplished by surface costaining live CD4^+^ cells with CD25 and CD69 before fixation and permeabilization with the FOXP3 buffer set. All events were collected on an LSRFortessa flow cytometer (BD) and analyzed with FlowJo (Tree Star). For Amnis ImageStream nuclear pSMAD2/3 quantification, PBMCs were stained with CD4 and pSMAD2/3 as performed for flow cytometry, with the addition of DAPI to create a nuclear mask. Events were recorded and quantified using IDEAS software (EMD Millipore).

Statistical analysis {#s15}
--------------------

In flow cytometry plots, data are presented as geometric mean fluorescence intensity (MFI) of the gated population. Unless otherwise indicated, remaining graphs represent the mean value ± SEM. Mann-Whitney, Wilcoxon matched pairs, and Student's *t* tests were used to test significance of associations as indicated. P-values \<0.05 were considered statistically significant. All statistical analyses were performed with Prism (v6.05; GraphPad Software).

Online supplemental material {#s16}
----------------------------

Fig. S1 shows primary gel filtration chromatography data. Fig. S2 shows increased T reg cells in *ERBB2IP^mut^* and *STAT3^mut^* patients are not associated with altered IL-2 responsiveness and are independent of the mutant STAT3 domain. Fig. S3 shows TGF-β can induce functionally active IL-4Rα expression in lymphocytes to promote STAT6-specific target expression. Fig. S4 shows greater IL-4Rα expression and increased GATA3 induction in *STAT3^mut^* and *ERBB2IP^mut^* naive CD4 lymphocytes are normalized by SMAD3 inhibition.
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